Morihiro Watanabe
Overview
Explore the profile of Morihiro Watanabe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamaguchi K, Fuse N, Komatsu Y, Fujii H, Hironaka S, Omuro Y, et al.
Jpn J Clin Oncol
. 2021 Feb;
51(6):879-885.
PMID: 33561262
Objective: We evaluated the efficacy and safety of first-line S-1 plus cisplatin in combination with cetuximab for Japanese patients with advanced gastric cancer, including gastroesophageal junction adenocarcinoma. Methods: This open-label,...
2.
Shitara K, Yamazaki K, Tsushima T, Naito T, Matsubara N, Watanabe M, et al.
Jpn J Clin Oncol
. 2020 Apr;
50(8):859-866.
PMID: 32328660
Objectives: Tepotinib (MSC2156119J) is an oral, potent and highly selective small molecule mesenchymal-epithelial transition factor (MET) inhibitor for which the recommended Phase II dose of 500 mg once daily has...
3.
Doi T, Fujiwara Y, Koyama T, Ikeda M, Helwig C, Watanabe M, et al.
Oncologist
. 2020 Apr;
25(9):e1292-e1302.
PMID: 32324927
Lessons Learned: Bintrafusp alfa had a manageable safety profile and demonstrated preliminary clinical activity in heavily pretreated patients with solid tumors (including hepatocellular carcinoma) with no or limited treatment options....
4.
Doi T, Iwasa S, Muro K, Satoh T, Hironaka S, Esaki T, et al.
Gastric Cancer
. 2018 Dec;
22(4):817-827.
PMID: 30515672
Background: Avelumab is a human anti-PD-L1 IgG1 monoclonal antibody that has shown antitumor activity in several advanced cancers. We report results from JAVELIN Solid Tumor JPN, a phase 1 trial...
5.
Kojima T, Yamazaki K, Kato K, Muro K, Hara H, Chin K, et al.
Cancer Sci
. 2018 Aug;
109(10):3253-3262.
PMID: 30099818
Sym004 is a 1:1 mixture of two antibodies targeting non-overlapping epitopes of the epidermal growth factor receptor that antagonizes ligand binding and induces receptor downregulation. In preclinical models, it has...
6.
Katakami N, Hida T, Nokihara H, Imamura F, Sakai H, Atagi S, et al.
Lung Cancer
. 2017 Feb;
105:23-30.
PMID: 28236981
Objectives: Unresectable stage III NSCLC (non-small cell lung cancer) confers a poor prognosis and interest is growing in the use of immunotherapy to improve outcomes for patients with this disease....
7.
Maruyama K, Selmani Z, Ishii H, Tai S, Cheng J, Akimoto S, et al.
Int Immunopharmacol
. 2012 Jan;
12(3):481-6.
PMID: 22245429
Fms-like tyrosine kinase 3 ligand ([Flt3 ligand], FL) stimulates proliferation and development of a wide range of hematopoietic cells including hematopoietic stem cells and myeloid and lymphoid progenitor cells. FL...
8.
Takahashi M, Miyazaki H, Furihata M, Sakai H, Konakahara T, Watanabe M, et al.
Clin Exp Metastasis
. 2009 Jul;
26(7):817-28.
PMID: 19629725
Bone is the most frequent site of breast cancer metastasis, and once such metastasis occurs, complete remission is extremely difficult to achieve. In an effort to define the mechanisms underlying...
9.
Rodriguez-Galan M, Reynolds D, Correa S, Iribarren P, Watanabe M, Young H
J Immunol
. 2009 Jun;
183(1):740-8.
PMID: 19535628
IL-12 is an excellent candidate for the treatment of cancer due to its ability to drive strong antitumor responses. Recombinant IL-12 protein is currently used in cancer patients; however, systemic...
10.
Takahashi M, Furihata M, Akimitsu N, Watanabe M, Kaul S, Yumoto N, et al.
Clin Exp Metastasis
. 2008 Mar;
25(5):517-29.
PMID: 18340424
To understand the mechanisms underlying bone marrow metastasis precisely, we established the highly metastatic 4T1E/M3 murine breast cancer cell line. 4T1 murine breast cancer cells were transfected with the neomycin...